Analysts Adjust Price Targets for Major Companies on January 23

On January 23, 2024, several research analysts revised their price targets for a range of publicly traded companies, reflecting changing market conditions and company performance. Notably, abrdn (LON:ABDN) saw its target price increase from GBX 190 to GBX 215, as recommended by Jefferies Financial Group Inc., which maintains a hold rating on the stock.

Abbott Laboratories (NYSE:ABT) experienced multiple price target adjustments from various firms. Evercore ISI reduced its target from $144.00 to $138.00, while maintaining an outperform rating. Piper Sandler cut its target from $150.00 to $135.00, also holding an overweight rating. Further adjustments were made by Oppenheimer Holdings, Inc., which lowered its target from $140.00 to $132.00, and The Goldman Sachs Group, Inc., which revised its target from $152.00 to $140.00, indicating a buy rating. Additionally, Raymond James Financial, Inc. and Royal Bank of Canada made cuts to their targets, establishing new targets of $130.00 and $135.00, respectively.

In the automotive sector, Adient (NYSE:ADNT) saw its target price rise from $24.00 to $26.00 after a recommendation from Stifel Nicolaus, who maintains a buy rating. Similarly, Allison Transmission (NYSE:ALSN) had its target increased from $97.00 to $109.00 by Morgan Stanley, which holds an equal weight rating on the stock.

Associated Banc (NYSE:ASB) had its target boosted by multiple firms. Royal Bank of Canada raised its target from $29.00 to $30.00, while Keefe, Bruyette & Woods and Piper Sandler also adjusted their targets to $30.00.

In the telecommunications sector, ARM (NASDAQ:ARM) had its target lowered from $180.00 to $135.00 by Morgan Stanley, which holds an overweight rating.

Utility giant Duke Energy (NYSE:DUK) saw its price target reduced by Royal Bank of Canada from $143.00 to $140.00, while maintaining a sector perform rating.

In the technology sector, Intel (NASDAQ:INTC) had multiple target adjustments. Evercore ISI raised its target from $41.10 to $45.00, while Benchmark Co. increased its target from $50.00 to $57.00.

These adjustments reflect a broader trend of analysts reassessing the market potential and performance of key players across different sectors. The revisions indicate both optimism and caution as companies navigate an evolving economic landscape. Investors will be keen to monitor these developments as they may impact stock performance in the coming weeks.